Full history for every metric is available with a Kvantra account
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS)
Key financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 2,110 | 1,872 | 1,775 | 2,026 | 2,240 | 1,599 | 1,100 |
| Operating profit | CNY m | 56 | -65 | |||||
| Net profit | CNY m | 65 | -506 | 23 | -76 | -72 | 70 | -62 |
| EPS reported | CNY | 0.10 | -0.09 | |||||
| Operating cashflow per share | CNY | -0.39 | -1.27 | |||||
| Capex per share | CNY | 0.05 | 0.03 | |||||
| FCF per share | CNY | -0.44 | -1.31 | |||||
| Free cash flow | CNY m | -310 | -1,040 | |||||
| Net debt | CNY m | 371 | 1,480 | |||||
| Book value equity | CNY m | 1,823 | 1,726 | |||||
| Book value per share | CNY | 2.56 | 2.46 | |||||
| Number of shares | m | 711.95 | 700.53 | |||||
| DPS (TTM paid) | CNY | 0.10 | 0.00 |
Financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 94.14 | - | |||||
| P/B LTM | x | 3.64 | 0.12 | |||||
| P/S LTM | x | 4.15 | 0.19 | |||||
| P/FCF LTM | x | -21.41 | -0.20 | |||||
| EV/EBITDA LTM | x | 39.13 | 35.39 | |||||
| EV/Sales LTM | x | 4.39 | 1.53 | |||||
| Earnings Yield LTM | % | 1.06% | -43.05% | |||||
| FCF Yield | % | -4.67% | -504.40% | |||||
| Quality | ||||||||
| ROE | % | 3.87% | -5.00% | |||||
| ROIC | % | 1.60% | -2.13% | |||||
| Operating margin | % | 3.52% | -9.22% | |||||
| Gross margin | % | 48.11% | 64.54% | |||||
| FCF/Sales | % | -19.39% | -117.03% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -28.64% | -45.51% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.02% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 96.19% | -66.39% | |||||
| FCF/Debt | x | -0.20 | -0.68 | |||||
| Net Debt/EBITDA | x | 2.14 | 151.67 | |||||
| EBIT/Net interest | x | 0.73 | -1.56 | |||||
| Net debt/market cap | % | 5.59% | 718.09% | |||||
| Net debt/Equity | x | 0.20 | 0.86 | |||||
| Gross debt/equity | x | 0.84 | 0.89 | |||||
Company overview
JiangSu WuZhong Pharmaceutical Development Co., Ltd., along with its affiliated entities, operates as a diversified Chinese enterprise with interests spanning the pharmaceutical, real estate, and chemical industries. The company is actively involved in the research, production, and sale of a broad spectrum of pharmaceutical products. These include medications targeting infections, digestive ailments, cardiovascular and cerebrovascular conditions, viral diseases, vitamin deficiencies, and hemostasis. Its pharmaceutical offerings also encompass immunomodulators, featuring biopharmaceuticals, traditional chemical drugs, and contemporary Chinese medicines. These treatments are available in diverse formats, such as intravenous solutions, injectable powders and liquids, capsules, granular forms, tablets, emulsions, and oral liquid preparations. In its chemical division, the company focuses on the development, manufacturing, and distribution of various dyes and their intermediates. Additionally, its real estate arm undertakes the construction of both market-rate and subsidized residential properties. Founded in 1994, the company is based in Suzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS)
JiangSu WuZhong Pharmaceutical Development Co., Ltd., along with its affiliated entities, operates as a diversified Chinese enterprise with interests spanning the pharmaceutical, real estate, and chemical industries. The company is actively involved in the research, production, and sale of a broad spectrum of pharmaceutical products. These include medications targeting infections, digestive ailments, cardiovascular and cerebrovascular conditions, viral diseases, vitamin deficiencies, and hemostasis. Its pharmaceutical offerings also encompass immunomodulators, featuring biopharmaceuticals, traditional chemical drugs, and contemporary Chinese medicines. These treatments are available in diverse formats, such as intravenous solutions, injectable powders and liquids, capsules, granular forms, tablets, emulsions, and oral liquid preparations. In its chemical division, the company focuses on the development, manufacturing, and distribution of various dyes and their intermediates. Additionally, its real estate arm undertakes the construction of both market-rate and subsidized residential properties. Founded in 1994, the company is based in Suzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free